Poliovirus type 2 — Drug Target
All drugs that target Poliovirus type 2 — marketed and clinical-stage. Includes 1 drug classes acting on this target.
Drug classes
Marketed (3)
- mOPV2 at 6 and 8 weeks of age · Centers for Disease Control and Prevention · Live attenuated vaccine · Immunology / Infectious Disease
mOPV2 is a live attenuated oral polio vaccine that stimulates immune responses against poliovirus type 2 to prevent poliomyelitis infection. - mOPV2 at 6 and 7 weeks of age · Centers for Disease Control and Prevention · Live attenuated vaccine · Immunology / Infectious Disease
mOPV2 is a live attenuated oral polio vaccine that stimulates immune responses against poliovirus type 2 to prevent poliomyelitis infection. - mOPV type 2 · University of Chile · Live attenuated vaccine · Immunology / Infectious Disease
mOPV type 2 is a live attenuated oral polio vaccine that stimulates immune responses against poliovirus type 2 through mucosal and systemic immunity.